Merck & Co., Inc.
Merck Anticipates Higher Than Expected First-Quarter Results; Raises Full-Year 2007 Earnings Per Share Guidance
Published in Lab Business Week, May 6th, 2007
Merck & Co., Inc. announced that, subject to final review of its first-quarter results, it anticipates its first-quarter earnings per share (EPS) will be $0.84, excluding restructuring charges related to site closures and position eliminations, and its reported EPS will be $0.78. Merck attributed these anticipated results to strong revenue performance across the Company's range of products. The Company also raised its anticipated 2007 full-year EPS range to $2.75 to $2.85, excluding restructuring charges related to site closures and position eliminations, and its full-year 2007 reported EPS range to $2.60 to $2.75.
This guidance does not reflect the establishment of any...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2007-05-06)
More Articles from Lab Business Week
- Biochemistry
Studies from Haskins Laboratories yield new data on biochemistry - Cell Biology
Research from Abbott Laboratories in the area of cell biology published - Chemotherapy
Reports from Haskins Laboratories highlight recent research in chemotherapy - Drug Development
Mylan Announces Final FDA Approval for Glipizide and Metformin Hydrochloride Tablets - Flu Vaccines
Carrington Subsidiary DelSite Biotechnologies Secures Antigen for Phase I Clinical Trial of Nasal Powder Influenza Vaccine - Hepatitis C Virus Therapy
Researchers from Abbott Laboratories report on findings in hepatitis C virus therapy - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
